PROMOMED showed revenue growth of over 75% in 2025. This corresponds to the forecast and is 6 times better than the market dynamics.

Corporate

For investors

25.02.2026

February 25, 2025, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly –PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the Group's operating results for the 12 months of 2025.

KEY INDICATORS

Revenue increased by 75.2%^{^[1]} YoY and reached 38 billion rubles. This is 6 times higher than the growth rate of the pharmaceutical market in monetary terms, which amounted to 11.6% according to IQVIA.
The ratio of budget and commercial sales was 34% and 66%, respectively. At the same time, both budget (+26%) and commercial (+118%) channels showed positive dynamics.
The share of Endocrinological and Oncological portfolios in revenue was 76% (61% in 2024).
In the Endocrinology segment, revenue increased by 163% YoY to RUB 21.6 billion. An important step in the development of the direction was the launch of the latest drug for the treatment of obesity and type II diabetes mellitus, Tirzetta®, which by the end of 2025 became the second largest absolute sales growth among all drugs in the retail segment of the Russian market[2].
In the Oncology segment, revenue increased by 43% YoY to RUB 7.0 billion. The growth was ensured, among other things, by the launch of the drug Pradetro® (INN: Apalutamide).

Indicators for the reporting period	2025	2024	y/y
Revenue, billion rubles, including segments:	37,6	21,4	75,2%
Endocrinology	21,6	8,2	163%
Oncology	7,0	4,9	43%
Other drugs[3]	9,0	8,3	8,0%
The share of drugs from the Endocrinological and Oncological portfolios in revenue, %	76	61	15 pp.
LP market, billion rubles,[4] including segments:	2 822	2 528	11,6%
relevant Endocrinology market (9 INN)	46,0	22,9	101%
relevant Oncology market (31 INN)	37,0	39,1	-5,4%
relevant market Other drugs (165 INN)	233	227	2,5%

"In 2025, PROMOMED has achieved excellent results. We promptly responded to the needs of the pharmaceutical market and provided patients with the most modern and unique medicines for Russia in our strategic areas. The Company's flagships in the Endocrinology segment — Tirzetta®, Velgia® and Velgia® ECO – showed impressive sales and market share growth, and the Oncological portfolio was complemented by the first Russian androgen receptor inhibitor, Pradetro® (INN: Apalutamide).

We went beyond the classical concept of a drug manufacturer and offered an innovative approach to the treatment process itself by introducing a subscription program for course-based medications. We are creating a full—fledged ecosystem of therapy - a continuous cycle of patient support, from treatment to lifestyle changes.

The management reporting data allows us to confidently confirm the financial forecast for 2025.

We expect our key focus markets to continue to grow at a faster pace in the new financial year, which will allow PROMOMED to remain a vibrant growth story on the Russian stock market."

Alexander Yefremov

General Director of PJSC PROMOMED

Показатели на отчетную дату	31.12.25		31.12.24	г/г
Кол-во препаратов в портфеле, шт.	364		343	21 шт.
Кол-во сотрудников	2 826		2 215	28%
Кол-во сотрудников в R&D	500		440	14%
Регистрационные удостоверения по нозологиям на 31.12.25
Эндокринология		22
Онкология		54
Неврология		66
Антибиотики		71
Общая терапия		110
Противовирусные		31
Иммунология		3
Ветеринария		5
Орфанные		2

РАЗВИТИЕ ЭКОСИСТЕМЫ ПРОДВИЖЕНИЯ ПРЕПАРАТОВ

В 2025 году ПРОМОМЕД представил первую в России программу подписки (promeka.ru), которая позволяет пациентам получать флагманские препараты курсового приёма со значительными скидками. Изначально в программу вошли решения для борьбы с сахарным диабетом и ожирением, сейчас подписка распространяется также на Амбене® Био, Амбене® Хондро и Брейнмакс®.

В начале 2026 года ПРОМОМЕД расширил систему подписки до полноценной экосистемы, включающей в себя полный цикл сопровождения пациента — от лечения до изменения образа жизни:

Цифровая платформа «Преображение» (vforme.pro), представляет возможность по оценке параметров тела, рекомендации по питанию и ЗОЖ, а также подборки тренировок — в том числе с профессиональными спортсменами.
Telegram-канал «ВФорме: похудение и ЗОЖ» (t.me/vforme_pro), где подробно разбираются подходы для комфортного похудения, освещается работа с пищевыми привычками, и предоставляются научные данные простым языком.

Комплексный подход к лечению заболеваний позволяет добиться не временного эффекта в терапии, а закрепления рациональных привычек питания и нового образа жизни пациентов.

ЭНДОКРИНОЛОГИЯ

В сегменте рынка Эндокринология выручка Группы за 2025 год выросла на 163% г/г и составила 21,6 млрд руб. Лидерами продаж в этом сегменте стали новые продукты Компании – Велгия®, Велгия® ЭКО и Тирзетта®. При этом релевантный рынок препаратов от сахарного диабета и ожирения в отчетном периоде вырос на 101% до 46 млрд руб.

Ключевые препараты в сегменте:

Тирзетта® — препарат нового поколения для терапии ожирения и сахарного диабета II типа, первый и единственный на российском рынке прямой конкурент американского Mounjaro. Препарат, свободный от фенолand, benzyl alcohol and other preservatives, which opens up the possibility of use for patients with hypersensitivity and liver and kidney diseases. In 2025, the drug became the second largest in absolute sales growth among the entire retail segment[5].
Velgia® is a drug based on the famous semaglutide, specially developed specifically for the treatment of obesity. In 2025, the drug entered the TOP 3[6] in terms of growth rates among all medicines in the retail segment, confirming the status of one of the most in-demand modern products.
Velgia® ECO is the only injectable semaglutide preparation without phenol and other preservatives, for the most sensitive and demanding patients.
Semaltara® is the first and currently the only semaglutide—based tablet drug in Russia for the treatment of type II diabetes mellitus with high efficacy in weight maintenance. Semaltara® is another step in ensuring the availability of innovative therapy, which means the appearance on the Russian market of an effective alternative to the imported drug Rebelsas®. The drug was launched at the end of 2025, but since January 2026 it has become an important driver of further sales growth.

ONCOLOGY

In the Oncology segment, revenue for 2025 increased by 43% YoY and amounted to 7.0 billion rubles. The relevant market showed a decrease of 5.4% to 37 billion rubles. and growth in physical terms by 6.7%.

The following drugs provided a key contribution to the Group's revenue growth:

Pradetro® (INN: Apalutamide) is the first Russian second—generation androgen receptor inhibitor for the treatment of prostate cancer. Its cost is almost 40% lower than imported direct and clinical analogues, while the quality and therapeutic properties are not inferior to foreign drugs.
a group of basic drugs for targeted and chemotherapy with its own technology for producing high-purity APIS, among which the best dynamics was shown by the antitumor drug Cabozantinib-PROMOMED.

OTHER DRUGS: GENERAL THERAPY, ORPHAN, ANTIVIRAL, NEUROLOGY, IMMUNOLOGY, ANTIBIOTICS AND OTHERS

In the Other drugs segment, revenue for 2025 increased by 8.0% YoY and reached 9.0 billion rubles. The growth of the relevant market was 2.5% to 233 billion rubles.

The impressive dynamics was demonstrated by the launch of Cladribine in 2024, an effective and safe drug for the treatment of multiple sclerosis. Sales of the drug increased 2.8 times YoY to 1.6 billion rubles. The Neurology segment also grew, where sales of Ambene® brand drugs increased 78% YoY to 1.1 billion rubles.

In the reporting period, 4 innovative drugs were launched on the market, with sales of about 0.5 billion rubles in the second half of 2025 alone:

Amberwin® Pulmo is the first in its class (first-in-class) drug from the class of short peptides connected to a fragment of succinic acid. It has anti-inflammatory and antioxidant effects, ensures the restoration of lung and tracheobronchial tract tissues in infectious and non-infectious lesions. The drug significantly reduces the degree of acute lung damage and helps prevent bacterial complications.
Migrenium® Neo is a new combined analgesic drug based on ibuprofen, the effect of which is enhanced by caffeine. This combination of components provides a rapid and pronounced effect on headaches, migraines, dysmenorrhea and other pains. In Russia, migraines affect about 20.8% of the adult population, which is almost 30 million people. This is one of the highest rates in the world.
Reitbufen® is an innovative new generation analgesic with the active ingredient dexibuprofen, characterized by high efficacy and a favorable safety profile. Dexibuprofen effectively inhibits the components of inflammation in pain syndrome, due to which the result is achieved faster and more pronounced.

Both analgesics belong to the over-the-counter market segment, which opens up qualitatively new opportunities for their promotion and commercialization.

Teduglutide is an orphan drug for the treatment of short bowel syndrome, rare and severeof the disease. The drug reduces dependence on parenteral nutrition to the point of complete rejection, strengthens the intestinal barrier function, reduces inflammation and significantly improves the quality of life: fewer hours on infusions, more mobility and freedom in everyday life. The volume of the relevant market in in 2025 amounted to 1.2 billion rubles.

In the reporting period, the development and registration certificates for drugs for the treatment of hepatitis C and orphan diseases, in particular spinal muscular atrophy (SMA), were completed.

VETERINARY MEDICINE

During the reporting period, the Group completed the registration process and launched two innovative veterinary drugs on the market.:

Amklav® VET is a combined antibiotic and a first—choice drug with increased effectiveness in the treatment of skin diseases, urinary tract infections, bacterial enteritis and respiratory bacterial infections in animals.

About the Company

PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market. PROMOMED celebrated its 20th anniversary in 2025. The ordinary shares of PJSC Promomed are traded on the Moscow Stock Exchange (ticker "PRMD").

The company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 360 medicines in the top 10 segments of the pharmaceutical market. The company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the company is an active participant in the system of ensuring national drug safety and import independence of the country.

Contacts

For investors	For the media
ir@promomed.pro	pr@promomed.pro

Statement of Limitation of liability

This message and the information contained therein are not:

an offer to purchase any securities,
an invitation to make offers to purchase any securities,
as part of such offers or invitations,
advertising of securities in the Russian Federation or other jurisdictions,
an offer to purchase medicines,
advertising of medicines,
by encouraging or recommending transactions,
and is also not subject to interpretation as such.

Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.

Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.

The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including the Federal Lawon April 22, 1996, No. 39-FZ "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.

Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page https://e-disclosure.ru/portal/company.aspx?id=38533.

The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.

The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.

The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.